Professor Shumway was walking hurriedly, as if someone’s life were at stake. Who knows? Maybe it was.
Heart transplant surgery is one of the most intricate and complex procedures in modern medicine.
The process usually goes something like this.
You remove a heart from a brain-dead donor and transplant it into someone who’s been waiting. How can you take a person’s heart out and put it in without killing them?
You have to do it right.
You use a machine called a heart-lung machine. It takes over the functions of the heart and lungs during surgery.
They had this device even in the 1970s.
The basic method is to pump blood out, oxygenate it, and then pump it back into the body.
You have to stop the heart during the operation and perform the surgery while it’s stopped, which……
is complicated.
That alone is difficult, but the hardships don’t end when the heart transplant is over.
When you transplant someone else’s organ into a patient, rejection can occur.
The recipient’s immune system often recognizes the newly transplanted organ as a foreign enemy and attacks it. This is called a host-versus-graft reaction.
Depending on the organ, the opposite can happen, too.
Specifically, it goes like this.
The host’s T lymphocytes see the major histocompatibility complex (MHC) presented by the transplanted organ, identify the cells as problematic, and kill them.
Usually, when that happens, the patient dies.
In the early days of organ transplantation, organs were transplanted without immunosuppression. The recipients and experimental animals who received them usually died soon after.
After that, doctors tried various methods of immunosuppression and tissue-compatibility tests.
The first person to receive a heart transplant in 1967 died nineteen days later.
As time went by……
Professor Shumway’s team developed the first effective method of heart transplantation.
In organ transplants during the 1970s, steroids and broad-spectrum immunosuppressants were used for immunosuppressive treatment. It was a logical choice.
The problem was that steroids had quite severe side effects, and broadly suppressing the immune system made patients extremely vulnerable to infection.
To put it in terms of a restaurant……
Well.
The chef died, so they hired a new chef who uses a wheelchair. They removed the front door to let the wheelchair in, and now rats are getting inside.
And the restaurant staff don’t recognize the new chef, so sometimes they beat the chef up.
End of metaphor.
To resist bacterial infections, the body employs a variety of processes, including macrophage migration, fever, and antibody production by B lymphocytes.
Broad immunosuppression and steroids block all of these processes. They tend to have severe side effects.
Cyclosporine, on the other hand, selectively inhibits the activity of T lymphocytes, preventing many of the side effects caused by immunosuppression.
Back to the story.
Professor Shumway was looking through the latest immunology journals in Stanford’s library.
“Where can I find cyclosporine?”
“Just a moment……”
I took a journal off the shelf and handed it to Professor Shumway. The professor immediately opened it and began to read, a grave expression on their face.
“This is it.”
“Immunology. By Dr. Borel. ‘Effects of the New Antilymphocytic Peptide Cyclosporine in Animals.’ It was published a few months ago.”
It was still only an animal study, but……
For scholars researching organ transplants, it was practically the Holy Grail.
Professor Shumway’s face turned pale as the professor scanned the journal. Shumway looked as if they were seeing a ghost.
“What is this……. Do you memorize every study published in the same year?”
“I try to keep up as best I can.”
Because I knew what to look for.
There had been plenty of cases where promising or urgently needed research had remained undiscovered for years simply because no one knew how to find it.
There was no search function in this era, either. The only way was to look through the journals one by one.
Professor Shumway took the paper with them.
“Why aren’t there residents like you in thoracic surgery? It’d be nice to have young doctors who did a little research and things like that.”
“Thank you.”
“Let’s see how quickly we can start clinical trials. If we can suppress the immune system without high-dose steroids or bone marrow suppressants, we could save a lot of transplant patients.”
I nodded gravely.
“You’ll be joining the research, too, right? This was your idea, after all.”
“Thank you.”
“Are there any organ transplant patients? I should start by finding out whether there are any kidney transplant patients right now……”
Muttering to themself, the professor left the library, saying we needed to start clinical trials soon so we could treat patients and publish the results.
I agreed.
***
I returned to the internal medicine residents’ room.
Anyway, I was going to turn what Professor Shumway and I had discussed earlier into a short paper. A simple letter laying out the principle would be enough.
A paper that would set the direction for future research.
What should I call it?
Let’s go with <The Mechanism of Organ Rejection and the Possibility of Selective Immunosuppressive Therapy>.
I immediately began writing.
I should send it as soon as possible.
I was planning to send this paper to Nature.
No matter how much the times changed, Nature was still the undisputed number one in academia. That was, unless you wanted to submit a case report.
I began writing the paper.
***
Let’s move things along.
Dean Richie looked over the draft of my paper, wearing a confused expression again.
My cyclosporine paper. Organ transplantation was bound to be a fairly conservative field.
“Do you understand how dangerous immunosuppression is for organ transplants? You’re proposing treatment with a drug discovered just this year……”
“I’m planning to work on it with Professor Shumway. We’ll combine it with mild immunosuppressive treatment using existing drugs, such as steroids.”
Dean Richie spent a little while explaining how organ transplantation worked and the risks involved in caring for immunosuppressed patients.
“Is the evidence solid?”
“Yes. The theory is solid.”
Historically, it was solid, too.
The dean furrowed his brow again. He seemed to have finally realized what he was reading.
“Dr. Parks. You wrote this paper, too. Still, does it make sense to cite your own paper as evidence for your argument?”
I nodded.
“Professor, the theoretical basis for the transplant rejection discussed here is the discovery of the antigen-presentation process, which revealed the principles of adaptive immunity.”
“That’s right. Why?”
“I wrote that paper in Professor McDevitt’s lab while we were studying H-2 proteins.”
Dean Richie let out a slow sigh, as if something important had just occurred to him.
“Well, I suppose everything you say must be right.”
“There’s no need to worry. Professor Shumway and I will proceed safely. We’ll also talk to the people who developed the drug.”
“All right. Good work. If you win an award, be sure to mention in your acceptance speech that I supported you.”
I bowed to Dean Richie and left the dean’s office.
***
Meanwhile. Across the ocean.
London, the editorial office at Nature’s headquarters.
It was the beating heart of the world’s academic community, an ivory tower that decided whether new research and papers would see the light of day or be buried.
“No, not this person again……?”
Dr. Fairchild frowned. The busy staff in Nature’s editorial office gathered around Dr. Fairchild.
“We haven’t even finished reviewing the paper about gene amplification, and this person is already back.”
“That’s right.”
Just thinking about this person gave them a headache.
Dr. Fairchild pressed their temples.
It was that person again.
An American doctor who had submitted ten papers to Nature alone. Not even a specialist, just a resident, and without a doctorate—only a master’s degree.
A genuinely bizarre person.
Most of the papers seemed to have been dashed off in a day or two, boiling complex material down as much as possible and focusing on case reports or proposed hypotheses.
Yet Nature had never once rejected a paper by this doctor.
Despite the strenuous efforts of the extremely conservative British doctors and the academic establishment.
The reason was simple……
The topics of the papers were just too important.
“Oh, it’s that person.”
“What could it be this time, I wonder?”
With a sigh, Dr. Fairchild opened the yellow envelope that had arrived from Stanford.
<The Mechanism of Organ Rejection and the Possibility of Selective Immunosuppressive Therapy>. Another short letter.
It would surely explain some groundbreaking new hypothesis or mechanism. This person had already done that ten times.
Dr. Fairchild sighed.
Just what was Stanford, and who was this person? Dr. Fairchild was curious enough to want to go to America and see for themself.
Hopefully, this time it would be a subject they could reject. The Nature editors pulled the paper from the brown envelope, their expressions grave.
-Organ transplant treatment has made remarkable progress over the past few years. However, the side effects of immunosuppressive treatment, such as infection, and the problem of organ rejection still remain.
Another bombshell of a topic.
-This paper proposes that cyclosporine, a newly discovered drug, may solve the problem of transplant rejection by applying what we know about the mechanisms of rejection.
This time, too……
It seemed to be another groundbreaking paper after all.